The main challenges in the use of immune checkpoint inhibitors(ICIs)are ascribed to the immunosuppressive tumor microenvironment and the lack of sufficient infiltration of activated CD8+T cells.Transforming the tumor ...The main challenges in the use of immune checkpoint inhibitors(ICIs)are ascribed to the immunosuppressive tumor microenvironment and the lack of sufficient infiltration of activated CD8+T cells.Transforming the tumor microenvironment(TME)from“cold”to“hot”and thus more likely to potentiate the effects of ICIs is a promising strategy for cancer treatment.We found that the selective BCL-2 inhibitor APG-2575 can enhance the antitumor efficacy of anti-PD-1 therapy in syngeneic and humanized CD34+mouse models.Using single-cell RNA sequencing,we found that APG-2575 polarized M2-like immunosuppressive macrophages toward the M1-like immunostimulatory phenotype with increased CCL5 and CXCL10 secretion,restoring T-cell function and promoting a favorable immunotherapy response.Mechanistically,we demonstrated that APG-2575 directly binds to NF-κB p65 to activate NLRP3 signaling,thereby mediating macrophage repolarization and the activation of proinflammatory caspases and subsequently increasing CCL5 and CXCL10 chemokine production.As a result,APG-2575-induced macrophage repolarization could remodel the tumor immune microenvironment,thus improving tumor immunosuppression and further enhancing antitumor T-cell immunity.Multiplex immunohistochemistry confirmed that patients with better immunotherapeutic efficacy had higher CD86,p-NF-κB p65 and NLRP3 levels,accompanied by lower CD206 expression on macrophages.Collectively,these data provide evidence that further study on APG-2575 in combination with immunotherapy for tumor treatment is required.展开更多
Invasive fungal infection is one of the major complication of severe burns which can induce local or systemic inflammatory response and cause serious substantial damage to the patient. The incidence of fungal infectio...Invasive fungal infection is one of the major complication of severe burns which can induce local or systemic inflammatory response and cause serious substantial damage to the patient. The incidence of fungal infection for burn victims is increasing dramatically during recent years. This guideline, organized by Chinese Society of Burn Surgeons, aims to standardize the diagnosis, prevention and treatment of burn invasive fungal infection. It can be used as one of the tools for treatment of major burn patients.展开更多
Background:Tumor hypoxia is considered an important factor in metastasis and disease relapse.Evofosfamide is a hypoxia-activated prodrug that selectively targets the hypoxic regions of solid tumors.As hypoxia-inducibl...Background:Tumor hypoxia is considered an important factor in metastasis and disease relapse.Evofosfamide is a hypoxia-activated prodrug that selectively targets the hypoxic regions of solid tumors.As hypoxia-inducible factor-1α(HIF-1α)is overexpressed in nasopharyngeal carcinoma(NPC)tissues,we performed the present study to evaluate the efficacy profile of evofosfamide in NPC.Methods:We evaluated the efficacy of evofosfamide as a single agent or combined with cisplatin(DDP)in the NPC cell lines CNE-2,HONE-1 and HNE-1,and in nude mouse xenograft tumor models.Results:Evofosfamide exhibited hypoxia-selective cytotoxicity in NPC cell lines,with 50%inhibition concentration(IC50)values of 8.33±0.75,7.62±0.67,and 0.31±0.07μmol/L under hypoxia in CNE-2,HONE-1 and HNE-1 cells,respectively.The sensitization ranged from ninefold to greater than 300-fold under hypoxia compared with normoxia controls.The combination of evofosfamide with DDP had a synergistic effect on cytotoxicity in the NPC cell lines by combination index values assessment.Cell cycle G2 phase was arrested after treated with 0.05μmol/L evofosfamide under hypoxia.Histone H2AX phosphorylation(γH2AX)(a marker of DNA damage)expression increased while HIF-1αexpression suppressed after evofosfamide treatment under hypoxic conditions.In the HNE-1 NPC xenograft models,evofosfamide exhibited antitumor activity both as a single agent and combined with DDP.Hypoxic regions in xeno-graft tissue were reduced after both evofosfamide monotherapy and combined therapy with DDP.Conclusions:Our results present preclinical evidence for targeting the selective hypoxic portion of NPC by evofosfa-mide as a single agent and combined with DDP and provide rationale for the potential clinical application of evofosfa-mide for the treatment of nasopharyngeal carcinoma.展开更多
基金supported by the Chinese National Natural Science Foundation Project(82073396,82303807)the Guangzhou Key Research and Development Plan(202206010141)+1 种基金the China National Postdoctoral Program for Innovative Talents(BX20230444)the China Postdoctoral Science Foundation(2023M734032).
文摘The main challenges in the use of immune checkpoint inhibitors(ICIs)are ascribed to the immunosuppressive tumor microenvironment and the lack of sufficient infiltration of activated CD8+T cells.Transforming the tumor microenvironment(TME)from“cold”to“hot”and thus more likely to potentiate the effects of ICIs is a promising strategy for cancer treatment.We found that the selective BCL-2 inhibitor APG-2575 can enhance the antitumor efficacy of anti-PD-1 therapy in syngeneic and humanized CD34+mouse models.Using single-cell RNA sequencing,we found that APG-2575 polarized M2-like immunosuppressive macrophages toward the M1-like immunostimulatory phenotype with increased CCL5 and CXCL10 secretion,restoring T-cell function and promoting a favorable immunotherapy response.Mechanistically,we demonstrated that APG-2575 directly binds to NF-κB p65 to activate NLRP3 signaling,thereby mediating macrophage repolarization and the activation of proinflammatory caspases and subsequently increasing CCL5 and CXCL10 chemokine production.As a result,APG-2575-induced macrophage repolarization could remodel the tumor immune microenvironment,thus improving tumor immunosuppression and further enhancing antitumor T-cell immunity.Multiplex immunohistochemistry confirmed that patients with better immunotherapeutic efficacy had higher CD86,p-NF-κB p65 and NLRP3 levels,accompanied by lower CD206 expression on macrophages.Collectively,these data provide evidence that further study on APG-2575 in combination with immunotherapy for tumor treatment is required.
文摘Invasive fungal infection is one of the major complication of severe burns which can induce local or systemic inflammatory response and cause serious substantial damage to the patient. The incidence of fungal infection for burn victims is increasing dramatically during recent years. This guideline, organized by Chinese Society of Burn Surgeons, aims to standardize the diagnosis, prevention and treatment of burn invasive fungal infection. It can be used as one of the tools for treatment of major burn patients.
基金supported by National Natural Science Foundation of China(Grant No.81502355,81502352).
文摘Background:Tumor hypoxia is considered an important factor in metastasis and disease relapse.Evofosfamide is a hypoxia-activated prodrug that selectively targets the hypoxic regions of solid tumors.As hypoxia-inducible factor-1α(HIF-1α)is overexpressed in nasopharyngeal carcinoma(NPC)tissues,we performed the present study to evaluate the efficacy profile of evofosfamide in NPC.Methods:We evaluated the efficacy of evofosfamide as a single agent or combined with cisplatin(DDP)in the NPC cell lines CNE-2,HONE-1 and HNE-1,and in nude mouse xenograft tumor models.Results:Evofosfamide exhibited hypoxia-selective cytotoxicity in NPC cell lines,with 50%inhibition concentration(IC50)values of 8.33±0.75,7.62±0.67,and 0.31±0.07μmol/L under hypoxia in CNE-2,HONE-1 and HNE-1 cells,respectively.The sensitization ranged from ninefold to greater than 300-fold under hypoxia compared with normoxia controls.The combination of evofosfamide with DDP had a synergistic effect on cytotoxicity in the NPC cell lines by combination index values assessment.Cell cycle G2 phase was arrested after treated with 0.05μmol/L evofosfamide under hypoxia.Histone H2AX phosphorylation(γH2AX)(a marker of DNA damage)expression increased while HIF-1αexpression suppressed after evofosfamide treatment under hypoxic conditions.In the HNE-1 NPC xenograft models,evofosfamide exhibited antitumor activity both as a single agent and combined with DDP.Hypoxic regions in xeno-graft tissue were reduced after both evofosfamide monotherapy and combined therapy with DDP.Conclusions:Our results present preclinical evidence for targeting the selective hypoxic portion of NPC by evofosfa-mide as a single agent and combined with DDP and provide rationale for the potential clinical application of evofosfa-mide for the treatment of nasopharyngeal carcinoma.
